Order Article Reprints

Kim D, Jang G, Hwang J, Wei X, Kim H, Son J, Rhee S-J, Yun K-H, Oh S-K, Oh C-M, et al. Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics. 2022; 14(12):2629. https://doi.org/10.3390/pharmaceutics14122629

Kim, Donghyun, Gyuho Jang, Jaetaek Hwang, Xiaofan Wei, Hyunsoo Kim, Jinbae Son, Sang-Jae Rhee, Kyeong-Ho Yun, Seok-Kyu Oh, Chang-Myung Oh, and et al. 2022. "Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects" Pharmaceutics 14, no. 12: 2629. https://doi.org/10.3390/pharmaceutics14122629

Kim, D., Jang, G., Hwang, J., Wei, X., Kim, H., Son, J., Rhee, S.-J., Yun, K.-H., Oh, S.-K., Oh, C.-M., & Park, R. (2022). Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics, 14(12), 2629. https://doi.org/10.3390/pharmaceutics14122629